FONDAPARINUX SODIUM Drug Interactions
Also known as: fondaparinux sodium
Fondaparinux sodium is a medication that helps prevent and treat blood clots. It works by thinning the blood, specifically by blocking a substance in the body called Factor Xa, which is involved in clot formation. This medicine is used to prevent deep vein thrombosis (DVT) after major surgeries like hip, knee, or abdominal surgery, and also to treat existing DVT or pulmonary embolism (PE).FONDAPARINUX SODIUM has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Combining naproxen with fondaparinux significantly increases your risk of bleeding, including serious and life-threatening bleeding episodes. This combination should generally be avoided.
Mechanism
Naproxen, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal defense and inhibit platelet aggregation. Fondaparinux is a synthetic selective inhibitor of activated factor Xa (anti-Xa), which prevents thrombin generation and clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, alongside increased gastrointestinal mucosal damage from the NSAID.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, but also intracranial hemorrhage or other major bleeding events. Studies show that NSAID use with anticoagulants can increase the risk of serious GI bleeding by 3 to 15 times compared to anticoagulants alone. Symptoms may include black, tarry stools, vomiting blood, unusual bruising, or prolonged bleeding from cuts. This combination should generally be avoided due to the high bleeding risk. If pain relief is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is absolutely required, use the lowest effective dose for the shortest duration possible, and closely monitor for signs of bleeding. Proton pump inhibitors (PPIs) may be considered for gastroprotection, but do not eliminate the bleeding risk. Regular monitoring of hemoglobin and hematocrit is recommended.
Combining etodolac (an NSAID) with fondaparinux (a blood thinner) significantly increases your risk of serious bleeding, including bleeding in the stomach or intestines. This combination should generally be avoided.
Mechanism
Etodolac inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and impairing platelet aggregation, which prolongs bleeding time. Fondaparinux is a selective factor Xa inhibitor that prevents thrombin generation, thereby inhibiting coagulation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, leading to a heightened risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding, intracranial hemorrhage, and other major bleeding events. Studies indicate that concomitant use of NSAIDs with anticoagulants can increase the risk of serious GI bleeding by 3 to 15 times compared to anticoagulant monotherapy. This combination should generally be avoided due to the high risk of serious bleeding. If co-administration is absolutely necessary, monitor patients closely for signs of bleeding (e.g., melena, hematemesis, bruising, petechiae, decreased hemoglobin). Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen, or discuss with the prescribing physician to assess the necessity of both medications.
Combining aspirin with fondaparinux significantly increases your risk of bleeding, including serious internal bleeding. Your doctor should carefully weigh the benefits against this increased risk.
Mechanism
Aspirin inhibits platelet aggregation irreversibly by blocking cyclooxygenase-1 (COX-1), leading to reduced thromboxane A2 production. Fondaparinux is a selective Factor Xa inhibitor, preventing thrombin generation and clot formation. The concomitant use of these agents results in additive antiplatelet and anticoagulant effects, severely impairing the body's ability to form clots.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can range from minor bruising or nosebleeds to severe gastrointestinal hemorrhage, intracranial bleeding, or other major bleeding events. This combination can increase the risk of serious bleeding by several fold compared to either drug alone, potentially leading to hospitalization or death. This combination should generally be avoided due to the high bleeding risk. If co-administration is deemed absolutely necessary, such as in specific high-risk cardiovascular conditions, patients require very close monitoring for signs of bleeding (e.g., blood in stool, dark tarry stools, unusual bruising, dizziness). Consider alternative therapies or dose adjustments if possible, and educate the patient on bleeding precautions.
Combining ibuprofen with fondaparinux significantly increases your risk of serious bleeding, especially in the stomach or intestines. Your doctor may need to adjust your medications or choose safer alternatives.
Mechanism
Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa. Fondaparinux is a selective factor Xa inhibitor, directly reducing thrombin generation. The concurrent use leads to additive antiplatelet and anticoagulant effects, severely impairing the body's ability to form clots.
Clinical Management
This combination substantially elevates the risk of major bleeding events, including gastrointestinal hemorrhage, intracranial bleeding, and hematoma formation. The risk of GI bleeding can be 3-15 times higher than with either drug alone, and overall major bleeding risk is significantly increased. Avoid concurrent use of ibuprofen and fondaparinux whenever possible. If an NSAID is absolutely necessary, consider a COX-2 selective inhibitor (e.g., celecoxib) with caution and close monitoring, or a non-NSAID analgesic. Monitor closely for signs of bleeding (e.g., black/tarry stools, unusual bruising, nosebleeds) and hemoglobin levels. Proton pump inhibitors may be co-prescribed to reduce GI bleeding risk if NSAID use is unavoidable.
Combining indomethacin with fondaparinux significantly increases your risk of serious bleeding, including internal bleeding. Your doctor will likely avoid this combination.
Mechanism
Indomethacin, a non-selective NSAID, inhibits cyclooxygenase (COX-1 and COX-2) enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Fondaparinux is a selective factor Xa inhibitor, which prevents thrombin generation and clot formation. The concomitant use results in additive antihemostatic effects, primarily through impaired platelet function from the NSAID and direct anticoagulant action from fondaparinux.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding, intracranial hemorrhage, and other major bleeding events. Studies show that combining NSAIDs with anticoagulants can increase the risk of major bleeding by 3 to 15 times compared to anticoagulant monotherapy. This combination should generally be avoided due to the high risk of serious bleeding. If an anti-inflammatory or analgesic is absolutely necessary, consider alternative therapies with lower bleeding risk, such as acetaminophen. Close monitoring for signs and symptoms of bleeding (e.g., melena, hematemesis, epistaxis, bruising) is crucial if co-administration cannot be avoided.
Combining celecoxib with fondaparinux significantly increases your risk of bleeding, including serious internal bleeding. This combination should generally be avoided due to the heightened danger.
Mechanism
Celecoxib, an NSAID, inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa, leading to increased bleeding risk. Fondaparinux is a selective factor Xa inhibitor that directly reduces thrombin generation, profoundly impairing the coagulation cascade. The concurrent use results in additive antihemostatic effects, significantly elevating the risk of hemorrhage.
Clinical Management
Patients are at a substantially increased risk for major bleeding events, including gastrointestinal bleeding, intracranial hemorrhage, and other site-specific bleeding. The risk of serious GI bleeding with NSAIDs and anticoagulants can be 3 to 15 times higher than with anticoagulants alone. Symptoms may include black, tarry stools, blood in urine, unusual bruising, or prolonged bleeding from minor cuts. This combination should be avoided if possible. If concomitant use is unavoidable, patients require very close monitoring for signs of bleeding, and the lowest effective dose for the shortest duration should be used. Consider alternative pain management strategies that do not increase bleeding risk, or alternative anticoagulants if clinically appropriate and safer. Proton pump inhibitors should be co-prescribed if GI bleeding risk is a concern.
Combining piroxicam with fondaparinux significantly increases your risk of serious bleeding, including internal bleeding. This combination should generally be avoided.
Mechanism
Piroxicam, a non-selective NSAID, inhibits cyclooxygenase enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Fondaparinux is a selective factor Xa inhibitor that prevents thrombin generation and clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, leading to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can range from minor ecchymoses to severe and life-threatening hemorrhage, including gastrointestinal bleeding, intracranial hemorrhage, and hematuria. The risk of serious gastrointestinal bleeding can be several-fold higher compared to either drug alone. This combination should be avoided if possible. If concomitant use is absolutely necessary, the patient's bleeding risk must be carefully assessed, and they should be closely monitored for signs of bleeding. Consider alternative pain management strategies that do not increase bleeding risk, or use a COX-2 selective NSAID with caution and for the shortest duration possible, along with gastroprotective agents.
Combining meloxicam with fondaparinux significantly increases your risk of serious bleeding, including stomach bleeding. It is generally recommended to avoid this combination.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal defense and inhibit platelet aggregation. Fondaparinux is a selective factor Xa inhibitor, which prevents clot formation. The combination results in additive antiplatelet and anticoagulant effects, alongside increased gastrointestinal mucosal damage from the NSAID.
Clinical Management
This interaction primarily leads to a significantly increased risk of bleeding, particularly gastrointestinal bleeding, but also bleeding at other sites. The risk of serious gastrointestinal bleeding can be several-fold higher (e.g., 3-15 times) when NSAIDs are combined with anticoagulants compared to either agent alone. Patients may experience symptoms such as black, tarry stools, blood in vomit, easy bruising, or prolonged bleeding from minor cuts. This combination should generally be avoided due to the high risk of serious bleeding. If both agents are absolutely necessary, extremely close monitoring for signs of bleeding is crucial, and a proton pump inhibitor (PPI) should be co-administered for gastroprotection. Consider alternative pain management strategies that do not involve NSAIDs, or alternative anticoagulants if clinically appropriate and feasible.
Combining diclofenac (an NSAID) with fondaparinux (a blood thinner) significantly increases your risk of serious bleeding, including stomach bleeding. Your doctor will likely recommend avoiding this combination.
Mechanism
Diclofenac inhibits prostaglandin synthesis, which reduces platelet aggregation and impairs the integrity of the gastrointestinal mucosa. Fondaparinux is a selective factor Xa inhibitor, which directly reduces thrombin generation and inhibits clot formation. The concurrent use of these agents results in an additive antiplatelet and anticoagulant effect, profoundly increasing the risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, but also bleeding from other sites. This can manifest as melena, hematemesis, hematuria, or excessive bruising. The risk of major gastrointestinal bleeding with NSAID plus anticoagulant therapy can be 3 to 15 times higher than with anticoagulant monotherapy. This combination should generally be avoided due to the high risk of bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID, though the bleeding risk remains significant. Close monitoring for signs and symptoms of bleeding is essential, and patients should be educated on what to watch for. Gastric protection with a proton pump inhibitor should be considered if the combination is unavoidable.
Combining ketorolac (an NSAID) with fondaparinux (an anticoagulant) significantly increases your risk of serious bleeding, including internal bleeding. This combination should generally be avoided.
Mechanism
Ketorolac inhibits prostaglandin synthesis, which can impair gastric mucosal protection and platelet aggregation. Fondaparinux is a selective Factor Xa inhibitor, preventing thrombin generation and clot formation. The concurrent use of these agents results in an additive antiplatelet and anticoagulant effect, significantly increasing the risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can be severe or life-threatening. This includes gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other forms of internal bleeding. The risk of major bleeding can be several-fold higher compared to monotherapy. This combination is generally contraindicated due to the high risk of severe bleeding. If an NSAID is absolutely necessary, consider alternatives with lower GI risk (e.g., celecoxib if cardiac risk allows) or topical NSAIDs, but even then, close monitoring for bleeding is essential. If fondaparinux cannot be interrupted, alternative pain management strategies that do not increase bleeding risk should be used.
For complete prescribing information:
View full FONDAPARINUX SODIUM monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.